One exception is alterations in DNA damage repair (DDR) genes, especially BRCA1/2, since BRCA-associated tumors, including breast, prostate and ovarian tumors, respond to poly–(adenosine diphosphate–ribose) polymerase (PARP) inhibitors and platinum-based therapy. This evidence concerns the gene BRCA1 and ovarian neoplasm.